AZD9496 First Time in Patients Ascending Dose Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: DRUG: AZD9496|DRUG: AZD9496
Sponsor: AstraZeneca